CD20 Antibodies & Proteins: Research Tools for B Cell Lymphoma and Autoimmune Disease

CD20 (MS4A1) is a B cell surface antigen expressed from pre-B cell through mature B cell stages but absent on plasma cells and stem cells, making it an ideal target for B cell-directed therapies.

Target Biology and Clinical Relevance

Rituximab (anti-CD20) was the first monoclonal antibody approved for cancer treatment (1997) and remains a cornerstone of lymphoma therapy. Second- and third-generation anti-CD20 antibodies (obinutuzumab, ofatumumab) have been developed with enhanced Fc-mediated effector functions.

CD20 is targeted through multiple mechanisms: direct signaling (apoptosis), ADCC (NK cell-mediated killing), CDC (complement-dependent cytotoxicity), and ADCP (antibody-dependent cellular phagocytosis). Research reagents for each mechanism include detection antibodies, blocking antibodies, and functional assay systems.

Research biosimilar rituximab is one of the most commonly used research-grade therapeutic antibodies, serving as a reference standard in biosimilar development programs, PK/ADA assays, and ADCC/CDC potency assays.

Anti-CD20 antibodies for flow cytometry must be validated on unfixed cells (CD20 is partially destroyed by some fixatives). Clones that work on paraformaldehyde-fixed cells should be specifically confirmed.

abinScience Product Coverage

References

1. Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer. 2012;12(4):252-264. doi: 10.1038/nrc3239

1. Hanahan D. Hallmarks of cancer: new dimensions. Cancer Discov. 2022;12(1):31-46. doi: 10.1158/2159-8290.CD-21-1059

2. Sharma P, Allison JP. The future of immune checkpoint therapy. Science. 2015;348(6230):56-61. doi: 10.1126/science.aaa8172

All products are for research use only. For technical support, contact order@abinscience.com.